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OBJECTIVE
To estimate long-term cumulative risk of end-stage renal disease (ESRD) after
diagnosis of type 2 diabetes.
RESEARCH DESIGN AND METHODS
Thisnationwidepopulation-based inception cohort study included421,429patients
with type 2 diabetes diagnosed in 1990–2011; patients were followed until the end
of 2013. Data linkage between several national health care registers in Finland,
covering 100% of the population, enabled the inclusion of almost all inhabitants who
started taking diabetes medication or were hospitalized for diabetes. Cumulative
risk of ESRD and hazard ratios [HR] for ESRD and death were estimated according
to age, sex, and time period of diabetes diagnosis.
RESULTS
Among 421,429 patients with type 2 diabetes, 1,516 developed ESRD and 150,524
died during 3,458,797 patient-years of follow-up. Cumulative risk of ESRDwas 0.29%
at 10 years and 0.74%at 20 years fromdiagnosis of diabetes. Riskwas higher among
men than among women (HR 1.93 [95% CI 1.72–2.16]), decreased with older age at
diagnosis (HR 0.70 [95% CI 0.60–0.81] for age 60–69 vs. 40–49 years), andwas lower
for those diagnosed in 2000–2011 than in 1990–1994 (HR 0.72 [95% CI 0.63–0.81]).
Patients diagnosed with diabetes in 2000–2011 had lower risk of death during
follow-up than those diagnosed in 1990–1994 (HR 0.64 [95% CI 0.63–0.65]).
CONCLUSIONS
Cumulative risk of ESRD is minimal among patients with type 2 diabetes compared
with their risk of death. Patients diagnosed with diabetes at an older age have a
lower risk of ESRD due to higher competing mortality.
Diabetes is amajor noncommunicable diseasewith an estimated global prevalence of
9% in 2014 (1). The number of adults with diabetes worldwide is expected to increase
from387million in 2014 to 592million in 2035,withmost having type 2diabetes (2,3).
One of the most devastating complications of diabetes is chronic kidney disease.
Relative to the general population, persons with diabetes have a 5- to 13-fold risk of
end-stage renal disease (ESRD) (4–6). ESRD extensively increases risk of death among
patients with diabetes (7–9), and diabetes is themost common cause of ESRD inmost
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industrialized countries (10); a study
of 18 European countries showed that
type 2 diabetes was the most frequent
renal disease leading to initiation of
renal replacement therapy (11).
Most earlier studies of the incidenceof
ESRD in diabetes have used prevalence
cohorts, which means that patients have
not been followed since their diabetes
diagnosis. Patients with all types of di-
abetes typically have been included, and
the incidence rate of ESRD has been
1–9 per 1,000 patient-years (4,12–14), with
larger estimates among African Ameri-
cans and those with a longer duration of
diabetes. Notably, a prevalence cohort
study from Italy including only patients
with type 2 diabetes showed that only
10 of 1,408 patients developed ESRD
over a 10-year follow-up (15). To our
knowledge, only two inception cohort
studies have addressed the incidence of
ESRD. The UK Prospective Diabetes Study
followed 5,097 patients with newly diag-
nosed type 2 diabetes, only 14 of whom
required renal replacement therapy dur-
ing the median follow-up of 10.4 years
(16). However, the cumulative risk was
not computed, and any subgroup anal-
yses would not have been possible
because of the small number of patients
who developed ESRD. A population-based
study from Saskatchewan, Canada, in-
cluded 90,429 incident cases of diabetes
among the adult study population, and
the results showed an almost threefold
risk of ESRD among indigenous patients
(17). Among nonindigenous patients, the
cumulative incidence of ESRD was;1–2%
at 20 years since the diabetes diagnosis.
We and others have estimated the
cumulative risk of ESRD in inception
cohorts of patients with type 1 diabetes
(18–21). Although type 2 diabetes is a
major cause of ESRD, cumulative risk of
ESRD after type 2 diabetes has been
diagnosed is not well known. Here, we
present the cumulative risk of ESRD
during a 24-year follow-up of a nation-
wide population-based cohort of 421,429
patients newly diagnosed with type 2
diabetes in 1990–2011.
RESEARCH DESIGN AND METHODS
Study Population
Patients with type 2 diabetes were iden-
tified from theDiabetes in Finland (FinDM)
database (22), which is a research register
created through cooperation between the
Finnish National Institute of Health and
Welfare, the Social Insurance Institution of
Finland, and the Finnish Diabetes Associ-
ation. The FinDM register was established
by using data from several national health
care databases such as the Hospital Dis-
charge Register (1969–1993), the Finnish
Health Care Register (1994–2011), the
Hospital Benchmarking database (1998–
2011), and the Medical Birth Register
(1987–2011). The Social Insurance Insti-
tution of Finland provided information
on patients entitled to reimbursement
for diabetes medication (1964–2011) and
purchases of prescribed antidiabetes
drugs (1993–2011). Among the patients in
the FinDM database, most (93%) were
identified by the use of antidiabetes med-
ication; 58%were identified on the basis
of their use of services taken from the
Hospital Discharge Register, the Finnish
Health Care Register, or the Hospital
Benchmarking database. Of these pa-
tients, 41% were identified only on the
basis of medication; 7%, on the basis of
services; and 52%, on the basis of both
medication and services. Almost all Finn-
ish inhabitants who started taking anti-
diabetes medication or were hospitalized
for diabetes were included in the FinDM
database, whereas persons who had di-
abetes but were not taking antidiabetes
medication or never received hospital
treatment were not included. The date
of diabetes diagnosis was defined as the
first registration of diabetes in any of the
four aforementioned registers. Patient
inclusion in the FinDM database has been
evaluated through the use of external data
sources (23).
We created a definition of type of
diabetes that was primarily based on
medicine purchases; it has been de-
scribed in detail elsewhere (22). Pa-
tients who receive continuous insulin
treatment but have never taken any
oral antidiabetes medication were de-
fined as having type 1 diabetes, whereas
all others were considered as having
type 2 diabetes. The diagnosis provided
by hospital providers was also used in
the definition. To ensure that we in-
cluded only patients with type 2 diabe-
tes, we excluded patients with diabetes
who were younger than 40 years old
when their diabetes diagnosis was reg-
istered. Data were available for 609,453
patients with type 2 diabetes first en-
tered in the database between 1972 and
2011. As initiation of dialysis among
patients with type 2 diabetes and elderly
patients was less frequent in the 1970s
and 1980s, we decided to analyze the
cumulative risk of ESRD only in patients
diagnosed with type 2 diabetes in more
recent yearsdbetween 1990 and 2011
(n = 422,224). Patients were excluded if
they had ESRD when type 2 diabetes was
diagnosed (n = 795). Thus the final in-
ception cohort included 421,429 patients
aged 40 years or older. Notably, during
the same time period, 7,451 patients
aged 20–29 years and 14,970 patients
aged 30–39 years were diagnosed with
diabetes according to the same criteria,
but they were not included in this
study. When presenting the incidence
rate of ESRD according to the time
period in which ESRD occurred, pa-
tient-years for all patients with type 2
diabetes contributing patient-years in
1990–2011 were included in the de-
nominator, as were patients diagnosed
with diabetes before 1990 who were not
included in the inception cohort.
Dataon initiationof renal replacement
therapy were retrieved from the Finnish
Registry for Kidney Diseases, which cov-
ers an estimated 97–99% of all patients
who have received chronic dialysis
and kidney transplantation since
1964 (24). ESRD was defined as receipt
of renal replacement therapy. The
FinDM database was linked to the Finn-
ish Registry for Kidney Diseases until
31 December 2013 by using individual
personal identity codes, which are used in
all administrative registers in Finland. Data
on deaths were retrieved from the Causes
of Death Register of Statistics Finland
(1971–2013). The FinDM Study was ap-
proved by the Ethics Committee of the
National Institute for Health and Welfare,
Helsinki, Finland, on 23 January 2014.
Statistical Analysis
Patients with type 2 diabetes were fol-
lowed from their first entry in the FinDM
database until ESRD or death occurred,
or until follow-up ended on 31December
2013. When calculating the cumulative
risk of ESRD, we accounted for death
as a competing risk event. Hazard ratios
(HR) of ESRD according to age group,
sex, and time period when type 2 di-
abetes was diagnosed were modeled by
using proportional subdistribution haz-
ards regression, which considered death
as a competing risk event (25). When
calculating risk of death, follow-up did not
end when ESRD occurred. Cumulative risk
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of death was estimated by using Kaplan-
Meier curves. Cox proportional hazards
regression models were fitted to provide
HR of death associated with age group,
sex, time of diabetes diagnosis, and time-
dependent occurrence of ESRD. All first-
degree interactions between explanatory
variables were tested. Incidence was
calulated by dividing the number of pa-
tients with ESRD by person-time at risk.
We used R statistical software version
3.2.2 (R Foundation for Statistical Com-
puting, Vienna, Austria; http://www
.r-project.org)with the cmprsk package
to calculate cumulative incidence (i.e.,
cumulative risk) of ESRD (cuminc func-
tion) and to perform proportional sub-
distribution hazards regression (crr
function). All other analyses were con-
ducted in SAS version 9.3 (SAS Institute
Inc.).
RESULTS
Of 421,429 patients diagnosed with type
2 diabetes in 1990–2011, 1,516 devel-
oped ESRD and 150,524 died before
the end of 2013. The total number of
patient-years of type 2 diabetes was
3,458,797 (Table 1). The median follow-
up was 6.82 years. A sex difference
was found for age distribution: 70% of
women and 55% of men were 60 years
or older when type 2 diabetes was
diagnosed.
The cumulative risk of ESRDwas 0.29%
at 10 years and 0.74% at 20 years since
the diagnosis of type 2 diabetes. The risk
was higher amongmen, but in both sexes
it decreased with increasing age (Fig. 1).
Figure 2 shows the incidence rate of
ESRD among patients diagnosed with
type 2 diabetes between 1990 and 2011.
The incidence rate increased with longer
duration of diabetes and was the highest
among those diagnosed with diabetes
during the earliest period, 1990–1994.
The proportional subdistribution haz-
ards regressionmodel showeddecreasing
HR for ESRDwith increasing age (Table 2).
Men had a 93% higher risk of ESRD than
women. The risk of ESRD was lower for
those diagnosed with diabetes during a
later time period. No statistically signifi-
cant first-degree interactions were de-
tected between the variables age, sex,
and period during which type 2 diabetes
was diagnosed.
As an alternative analysis, the inci-
dence rate of ESRD was calculated among
all prevalent cases of type 2 diabetes in
the time periods 1990–1999 and 2000–
2011, thus including patients who were
diagnosed with type 2 diabetes before
1990 but who contributed patient-years
in 1990–2013 (Supplementary Fig. 1).
During a total of 4,345,251 patient-years,
2,127 patients developed ESRD, resulting
in an incidence rate of 0.49 per 1,000
patient-years (95% CI 0.47–0.51). The
incidence rate was higher among men
(0.66 [95% CI 0.63–0.70]) than among
women (0.33 [95% CI 0.31–0.35]) and in
2000–2013 (0.53 [95% CI 0.51–0.56])
than in 1990–1999 (0.37 [95% CI 0.34–
0.41]). The incidence rate of ESRD had
increased most among men older than
70 years. For both men and women, the
incidence rate of ESRD peaked among
those aged 60–79 years.
Among patients diagnosed with type
2 diabetes between 1990 and 2011, the
cumulative risk of death was 34% at
10 years and 64% at 20 years since the
diagnosis of diabetes. The HR of death
increased with increasing age (Table 2).
Patients aged 70–79 years when di-
abetes was diagnosed had an eight-
fold risk of death during the follow-up
compared with those aged 40–49 years.
When calculating HR for death, occurrence
of ESRD was included in the multivariable
model as a time-dependent variable (not
shown in Table 2), and ESRD increased the
risk of death 4.2-fold during follow-up.
Excluding the time-dependent variable
ESRD caused marginal changes in the
model parameters. In the interaction
analysis, sex modified the effects of age
and ESRD on HR for death. Among men,
ESRD increased risk of death 3.8-fold
and among women, 5.6-fold. Age (70–
79 vs. 40–49 years) showed an HR for
death of 7.4 among men and 9.8 among
women. Also, a statistically significant
interaction occurred between age and
ESRD during follow-up, showing a weaker
association between ESRD and risk of
death among those aged 70 years or
older (HR 3) than among those younger
than 60 years (HR 5).
CONCLUSIONS
This large, nationwide inception cohort
study shows that the risk of ESRD is
lowdonly 0.74% at 20 years from the
diagnosis of diabetesdamong more than
420,000 patients with type 2 diabetes
who were followed for up to 24 years.
During the follow-up (;3.5 million
patient-years), only 1,516 patients
Table 1—Number of patients diagnosed with type 2 diabetes in 1990–2011
and numbers of patient-years, ESRD cases, and deaths until the end of 2013
according to age and sex
Age-group (years), by sex
Patients with
type 2 diabetes Patient-years ESRD cases Deaths
40–49
Males 31,465 317,663 239 5,100
Females 18,520 192,669 73 1,695
Total 49,985 510,332 312 6,795
50–59
Males 64,502 586,784 356 13,368
Females 43,583 434,523 142 5,618
Total 108,085 1,021,307 498 18,986
60–69
Males 63,926 498,862 297 21,916
Females 56,965 545,698 165 15,790
Total 120,891 1,044,560 462 37,706
70–79
Males 40,272 249,330 133 22,503
Females 56,734 433,455 93 29,804
Total 97,006 682,785 226 52,307
$80
Males 13,145 51,605 11 10,085
Females 32,317 148,208 7 24,645
Total 45,462 199,813 18 34,730
All $40
Males 213,310 1,704,244 1,036 72,972
Females 208,119 1,754,553 480 77,552
Total 421,429 3,458,797 1,516 150,524
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developed ESRD, while more than
150,000 died. The number of deaths
was 100-fold higher than the number of
ESRD cases. Thus death was a main com-
peting risk event, and it was accentuated
in the older age groups. The cumulative
risk of ESRD was highest among those
diagnosed with diabetes at the youngest
age, 40–49 years; risk decreased contin-
uously while mortality increased among
the older age groups. By contrast, the
incidence rate of ESRD was highest
among patients aged 60–79 years,
which reflects the typical age at which
ESRD occurs among people with type 2
diabetes. Male patients had a twofold
risk of ESRD; this male predominance
is a common finding for all causes of
ESRD (10).
The study also shows that cumulative
risk of ESRD was smaller in recent years
than at the beginning of the 1990s. By
contrast, the incidence rate of ESRD has
increased among all prevalent cases of
type 2 diabetes, which demonstrates
that the nature of the incidence rate
is different from that of cumulative risk.
This may be explained by longer diabetes
duration of the patients considered in
the 2000–2013 period. We show that the
incidence rate of ESRD increases with
duration of diabetes, which was also
observed earlier (12). Our finding of a
decrease in patients’ cumulative mor-
tality reflects improved diabetes care.
Our study has several strengths. The
study population is based on a compre-
hensive linkage of data from multiple
national health care registers, providing
complete coverage of the Finnish pop-
ulation. All people with type 2 diabetes
in Finland were included from when
antidiabetes medication was initi-
ated; that is, this inception cohort in-
cluded a clearly specified starting point
for follow-up. Data on death were also
retrieved from a complete national da-
tabase. Data on renal replacement ther-
apy were estimated to be 97–99%
complete. Our study is unique in that
it is, to our knowledge, the only nation-
wide and by far the largest inception
cohort study of the risk of ESRD among
people with type 2 diabetes. This enables
a much more accurate estimation of the
cumulative risk of ESRD than is available
from earlier studies.
Some limitations of the study warrant
discussion. We did not have information
on earlier stages of chronic kidney dis-
ease, such as albuminuria or elevated
creatinine, but this did not affect the
estimates of cumulative risk of ESRD.We
also lacked information on clinical pa-
rameters such as HbA1c, blood pressure,
or dyslipidemia. Our study did not in-
clude patients with diabetes who re-
ceived only dietary treatment, nor did
it include people with undiagnosed di-
abetes. Two large, population-based
health surveys were performed in Fin-
land in 2000 and 2011, and they showed
that 25–30% of respondents with self-
reported diabetes received only dietary
treatment (26). In a cross-sectional study,
the glucose tolerance test was performed
in 2004 on randomly selected Finnish
inhabitants aged 45–74 years (27). Re-
sults showed that 16% of men and 11%
of women had diabetes, and in only less
than half of those people had diabetes
been diagnosed before. Thus, it is clear
Figure 1—Cumulative risk of ESRD, by age-group, among male and female patients with type 2 diabetes detected in 1990–2011.
Figure 2—Incidence rate of ESRD per 1,000 patient-years, by period during which type 2 diabetes
was diagnosed and by the duration of type 2 diabetes in the inception cohort.
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that our study merely includes a selec-
tion from among all patients with type 2
diabetes, as a considerable proportion
of people with diabetes remain undiag-
nosed. However, this is also the case in
other population-based studies, be-
cause nearly half of all diabetes cases
globally are estimated to be undiag-
nosed (28). We defined ESRD as receipt
of renal replacement therapy, but not
all patients with ESRD receive dialysis
therapy or a renal transplant. At Helsinki
University Hospital, all decisions to ini-
tiate renal replacement therapy have
been registered since the 1990s. In;20%
of patients with ESRD, renal replacement
therapy was not initiated (E. Honkanen, A.
Esktrand, personal communication). In the
1970s and 1980s, renal replacement ther-
apy was hardly ever initiated for patients
with type 2 diabetes, but the number of
these patients entering dialysis annually
increased sharply through the 1990s until
2000, after which the rate has remained
relatively unchanged (24). It should also
be noted that the annual number of
people diagnosed with type 2 diabetes
increased during the study period, pro-
bably as a consequence of increased
screening for type 2 diabetes, which leads
to earlier detection or detection of cases
that previously would have remained
undetected. We assume that earlier de-
tection of diabetes is connected to lower
cumulative risk of complications. For
this reason, cumulative risk of ESRD
between time periods of diabetes diag-
nosis should be compared carefully.
Most earlier studies of ESRD risk in
patients with diabetes were based on
prevalence cohorts (4,12–15), which
means that, contrary to inception co-
hort studies, patients were not included
in the study at any specified point in the
early course of diabetes (e.g., at time of
diagnosis) and that the period since
diabetes was detected varied. The over-
all incidence rate of ESRD has varied
between 1 and 9 per 1,000 patient-years.
In Caucasians, the incidence rate of ESRD
is lower: between 1 and 4 per 1,000
patient-years (13,15), which is still
higher than the incidence rate of 0.49
per 1,000 patient-years reported here.
The difference may be explained by the
relatively low overall incidence of renal
replacement therapy in Finland (10).
Notably, in the UK Prospective Diabe-
tes Study, 14 of 5,097 patients (0.3%)
with type 2 diabetes developed ESRD,
which is similar to the cumulative risk
of 0.29% at 10 years in our study (16).
Patients’ risk of developing ESRD after
type 2 diabetes has been diagnosed can
be reliably estimated only by calculating
the cumulative incidence of ESRD in
large inception cohort studies. To our
knowledge, only one such study has
been published. Jiang et al. (17) com-
pared the cumulative incidence of ESRD
between indigenous and nonindigenous
patients diagnosed with diabetes in the
Canadian province of Saskatchewan.
Among nonindigenous persons, the risk
of ESRDdless than 1% at 10 years and
1–2% at 20 years since diagnosis of
diabetesdwas comparable to our find-
ings. Patients aged 60 years or older
when diabetes was diagnosed had a
lower cumulative risk of ESRD due to
higher competing mortality, which also
was the case in our study. The similarity
of our findings in northern Europe with
those from Canada supports the gener-
alizability of our results to other highly
developed countries.
Our study shows that risk of ESRD is
small amongpeoplewith type2diabetes.
This may seem unexpected, because a
substantial proportion of patients are
entering early stages of chronic kidney
disease, with 25% of patients having
microalbuminuria and 5% having macro-
albuminuria 10 years after their diabe-
tes diagnosis (16). These early stages of
kidney disease are associated with in-
creased premature mortality; this con-
tributes to the fact that relatively few
patients develop ESRD, as death is a
common competing risk event. However,
diabetes is the most common cause of
ESRD in most industrialized countries,
and because of a high and increasing
prevalence of diabetes among the gen-
eral population, a considerable absolute
number of patients with type 2 diabetes
need dialysis therapy (10,11). Our find-
ings are important for clinicians who
inform patients with type 2 diabetes
about the associated risks and compli-
cations. As type 2 diabetes is a common
disease, our study also has implications
for policy makers. Notably, people di-
agnosed with type 2 diabetes at an older
age have a lower risk of ESRD and a higher
risk of death than those diagnosed at a
younger age. The cumulative risk of ESRD
and death has decreased since the early
1990s amongpeoplewith type2diabetes.
Thismay be the result of improvements in
Table 2—HR of ESRD and death among patients diagnosed with type 2 diabetes in 1990–2011 and numbers of patient-years,
ESRD cases, and deaths until the end of 2013 according to age-group and sex
Patients with





Age at diabetes diagnosis (years)
40–49 49,985 510,332 312 6,795 1 1
50–59 108,085 1,021,307 498 18,986 0.82 (0.71–0.94) 1.6 (1.5–1.6)
60–69 120,891 1,044,560 462 37,706 0.70 (0.60–0.81) 3.2 (3.2–3.3)
70–79 97,006 682,785 226 52,307 0.45 (0.37–0.54) 8.3 (8.0–8.5)
$80 45,462 199,813 18 34,730 0.09 (0.05–0.14) 22.8 (22.2–23.4)
Sex
Female 208,119 1,754,553 480 77,552 1 1
Male 213,310 1,704,244 1,036 72,972 1.93 (1.72–2.16) 1.5 (1.5–1.6)
Period when type 2 diabetes
was diagnosed
1990–1994 69,514 845,281 508 50,464 1 1
1995–1999 75,193 878,826 387 40,722 0.77 (0.67–0.88) 0.82 (0.81–0.83)
2000–2011 276,722 1,734,690 621 59,338 0.72 (0.63–0.81) 0.64 (0.63–0.65)
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diabetes care, but it may also reflect the
inclusion in our study cohort of people at
an earlier stage of diabetes.
In conclusion, although type 2 diabe-
tes is a major cause of ESRD, our study
indicates that cumulative risk of ESRD in
people with newly diagnosed type 2 di-
abetes is conspicuously low: only 0.74%
at 20 years after diabeteswas diagnosed.
Moreover, the cumulative risk of ESRD
decreases with older age at the time of
diabetes diagnosis, mainly because of
competing mortality. Future research
should focus on how hypertension, hy-
perglycemia, dyslipidemia, and other
treatable clinical factors affect the risk
of people with type 2 diabetes develop-
ing ESRD.
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21. Möllsten A, Svensson M, Waernbaum I,
et al.; Swedish Childhood Diabetes Study Group;
Diabetes Incidence Study in Sweden; Swedish
Renal Registry. Cumulative risk, age at onset, and
sex-specific differences for developing end-stage
renal disease in young patients with type 1
diabetes: a nationwide population-based cohort
study. Diabetes 2010;59:1803–1808
22. SundR,KoskiS.FinDMII.OntheRegister-Based
Measurement of the Prevalence and Incidence of
Diabetes and Its Long-Term Complications. A Tech-
nical Report. Tampere, Finland, Finnish Diabetes
Association, 2009
23. Sund R, Harno K, Ranta S, et al. Evaluation of
case inclusion in two population-based diabetes
registers. Finn JeHealtheWelfare2010;2:136–146
24. Finnish Registry for Kidney Diseases. Report
2014. Helsinki, Finland, Finnish Registry for Kid-
ney Diseases, 2016
25. Fine JP, Gray RJ. A proportional hazards
model for the subdistribution of a competing
risk. J Am Stat Assoc 1999;94:496–509
26. Koskinen S, Lundqvist A, Ristiluoma N (Eds.).
Health, Functional Capacity and Welfare in Fin-
land in 2011. Helsinki, Finland, National Institute
for Health and Welfare, 2012 (Report 68/2012)
[in Finnish]
27. Peltonen M, Korpi-Hyövälti E, Oksa H, et al.
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